Coiro, Stefano
Porot, Guillaume
Rossignol, Patrick
Ambrosio, Giuseppe
Carluccio, Erberto
Tritto, Isabella
Huttin, Olivier
Lemoine, Simon
Sadoul, Nicolas
Donal, Erwan
Zannad, Faiez
Girerd, Nicolas
Article History
Received: 13 April 2016
Accepted: 22 November 2016
First Online: 20 December 2016
Competing interests
: Faiez Zannad received fees for serving on the board of Boston Scientific; consulting fees from Novartis, Takeda, AstraZeneca, Boehringer Ingelheim, GE Healthcare, Relypsa, Servier, Boston Scientific, Bayer, Johnson & Johnson, and Resmed; and speaker’s fees from Pfizer and AstraZeneca. Nicolas Girerd received Board Membership Fees from Novartis. Patrick Rossignol received fees from Relypsa and Board Membership Fees from Novartis. Giuseppe Ambrosio received consulting fees and speaker’s fees from Angelini, Behring, Menarini, Merck. All other authors have no conflict of interest to declare.